Search published articles


Showing 4 results for Multiple Myeloma

Dr. M. Khani, Dr. K. Alimoghadam, Dr. A. Karimi, A. Mousavi, Dr. A. Ghavamzadeh,
Volume 6, Issue 1 (5-2009)
Abstract

  Abstract

 Background and Objectives

 Multiple myeloma (MM) is a clonal disorder of hematopoietic stem cell. We have been doing in-patient stem cell transplant (SCT) in Iran since 1991 however, this is the first time we have decided to embark on out-patient SCT.

 

 Materials and Methods

 In this cohort study, the selected Multiple Myeloma patients received outpatient stem cell transplantation. They were then discharged and followed by an out-patient SCT team including a general physician, a staff nurse and a care giver during the neutropenic period. All data were collected and analyzed using ANOVA test, Caplan mayer curve and SPSS 11.5.

 

 Results

 Forty four patients received in-patient or out-patient autologus SCT. The rates of median hospital stay were 28 (19-54) and 6.5 days (1-8) in in-patient and out-patient groups, respectively. Median home visit by team was 10.5 days. There were not significant differences (p<0.001) between these groups as far as apheresis days, granulocyte colony stimulatig factor (GCSF) dosage as mobilization, number of mono nuclear cell (MNC) or cluster of differentiation (CD)34+ cell parameters are concerned. There was also a significant decrease in total cost of SCT in out-patient group by 70% (p<0.017) including visit cost with 80% decrease (p<0.01), drug cost with 50% (p<0.004), laboratory cost with 70% (p<0.02), and hospital cost with 70% (p<0.04).

 

 Conclusions

 Our results show that out-patient autolgous SCT in multiple myeloma patients is feasible and its complications are manageable. Significant reduction in cost and bed requirement is also inevitable.

  

  Key words : Multiple Myeloma, Stem Cell Transplantation, Apheresis


Dr. S. Abroun, N. Saki,
Volume 7, Issue 3 (8-2010)
Abstract

  Abstract

 Background and Objectives

 Multiple Myeloma (MM) is a plasma cell disorder witch accounts for about 10% of all hematologic cancers 99% of patients diagnosed are older than 40 years of age. The aim of this study is to evaluate the recognized cellular and molecular factors effective on the emergence and development of MM.

 

 Materials and Methods

 In the present study, 150 articles about genetic translocation, osteoclast and osteoblast cells, chemokines, signaling pathways, and Multiple Myeloma published in recent years were firstly selected to be reviewed. Out of this number, 69 which applied to cellular and molecular biology of MM were selected to be studied.

 

 Results

 Bone lesions and pathological fractures are the most important complications of Multiple Myeloma. Recurrent infection, renal insufficiency, hyperproteinemia, amyloidosis, hypercalcemia, decrease of alkaline phosphatase, and osteocalcin are other complications which are mostly caused by cell-cell interaction, chemokine, and immunoglobulin signal induction.

 

 Conclusions

 The results show that infiltration of tumor cells like myeloma cells is due to secretion of some factors from BM cells as well as the presence of calcium and iron whose concentration is high in BM.

  

 Key words : Multiple Myeloma, Bone osteolytic lesions, Osteoclast, Osteoblast 

 


Sh. Kazemzadeh, Dr. A.r. Farsinejad, J. Sabour Takanlu, S. Kaviani, Dr. A. Atashi, Dr. M. Soleimani, Dr. S. Abroun,
Volume 13, Issue 3 (8-2016)
Abstract

Abstract

Background and Objectives

MicroRNAs play a crucial role in controlling the innate and adaptive immune responses, inflammation, cell growth, and apoptosis by regulating gene expression at post-transcriptional level. In addition, many microRNAs act as oncogenes, tumor suppressors, and the mediators of cancer stem cells. MiR-146a is one of the important microRNAs in inflammatory diseases and tumors which has a dual effect on cancers and acts as a tumor promoter or a tumor suppressor. The present study aimed to evaluate the expression of miR-146a in multiple myeloma cell lines (L363, LP1, RPMI 8226 and KMM1) in comparison with normal leukocytes.

Materials and Methods

In this experimental study, four myeloma cell lines and peripheral blood leukocytes isolated from healthy individuals were cultured under specific conditions. After RNA extraction, miR-146a expression was measured by quantitative Real Time PCR.

Results

The research results showed that the expression of miR-146a in multiple myeloma cell lines was significantly decreased compared with normal leukocytes. Data analysis also revealed that the expression of miR-146a was decreased in average of 0.32 ± 0.2 folds in L363 cell line and for LP1, RPMI 8226, and KMM1 cell lines in average of 0.03 ± 0.07, 0.0035 ± 0.02, 0.0022±0.001 folds, respectively (p < 0.01).

Conclusions 

The researchers' results suggest that miR-146a can act as a tumor suppressor in leukocytes, and the decreased expression of this microRNA in myeloma cells is likely to be effective at the onset and progression of multiple myeloma.


Z. Ameri, S. Ghiasi, Dr. A.r. Farsinejad, M. Ehsan, S. Aghajani, N. Pur Yazdan Panah, Sh. Kazemzadeh, Dr. A. Fatemi,
Volume 14, Issue 3 (9-2017)
Abstract

Abstract
Background and Objectives
Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. This study aimed to investigate the effects of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on apoptosis of myeloma cell line U266.
 
Materials and Methods
In an Experimental study, U266 cells were treated with different concentrations of MST-312 at different times; then, cell viability by trypan blue exclusion assay, cell metabolic activity by MTT assay, and cell apoptosis by Annexin V Apoptosis Detection Kit were measured. To further investigate apoptosis, BAX and BCL2 gene expression of the treated cells was investigated by the quantitative Real-Time PCR.
 
Results
MST-312 exerted a dose-dependent short-term cytotoxic effect on myeloma cells. Over 50% decrease in the viability of treated cells was seen in 8 μM concentration of MST-312 within 48 h. The cytotoxic effect of MST-312 was concentration-dependent, with approximately 25, 46, and 62% reduction in metabolic activity after 48 h exposure to 2, 4, and 8 μM of MST-312, respectively. Gene expression analysis showed downregulation of antiapoptotic gene Bcl-2 and upregulation of apoptopic gene BAX.
 
Conclusions 
Inhibition of telomerase activity by MST-312 represents a novel treatment strategy for Multiple Myeloma cancer.
 

 



Page 1 from 1     

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb